New drug duo aims to tame stubborn blood cancer
NCT ID NCT06575686
First seen Jan 24, 2026 · Last updated Apr 20, 2026 · Updated 16 times
Summary
This study is testing whether a combination of two drugs, epcoritamab and tazemetostat, is safe and effective for adults with follicular lymphoma that has come back or not responded to prior therapy. The drugs work together to help the immune system attack cancer cells and block their growth. The trial is currently suspended and was enrolling about 33 people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
Conditions
Explore the condition pages connected to this study.